Valneva SE is a France-based company that specializes in the development, manufacture and commercialization of vaccines to protect people from infectious diseases through preventative medicine. The Company's portfolio includes two commercial vaccines for travelers: IXIARO/JESPECT, for the prevention of Japanese Encephalitis, and DUKORAL, which is indicated for the prevention of cholera and, in some countries, prevention of diarrhea caused by Enterotoxigenic escherichia coli (ETEC). The Company has also vaccines in development, including candidates against Lyme disease, COVID-19 and chikungunya. Its technologies and services segment cooperates with various pharmaceutical companies using its platform: EB66 vaccine production cell line and IC31 adjuvant. The Company is focused on research and development (R&D) programs, as well as holds investment in product candidates and commercial products.
高成長
同社の収益は過去3年間にわたり着実に増加しており、年平均で33.76%の成長率を示しています。
高い利益成長
同社の純利益は業界をリードしており、最新の年間純利益はUSD 205.61Mです。
割高
同社の最新のPEは-3.75で、過去3年間の水準と比較して高値圏にあります。
機関投資家の売り越し
最新の機関投資家の保有株数は5.21M株で、前四半期比で5.60%減少しています。
市場活動が低調
同社への投資家の関心は低下しており、20日間の売買回転率は-0.57です。